MetaCap

Aprea Therapeutics (APRE) vs XTL Biopharmaceuticals (XTLB)

Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.

Summary

XTL Biopharmaceuticals is the larger company by market cap ($3.4 million vs $3.2 million), about 1.0 times the size.

Summary generated from market data by MetaCap's automated system. Methodology

Relative performance

APRE-62.15%XTLB-30.81%
+5%-30%-65%
Oct 7, 20261 yearNov 20, 2026
APRE-62.11%XTLB-30.81%
+5%-30%-65%
Oct 5, 20265 yearsNov 16, 2026

Percent change in share price from the first common trading day shown; excludes dividends.

Head-to-head

APRE versus XTLB key metrics
MetricAPREXTLB
Share price$0.229$1.37
Market cap$3.25M$3.37M
1-day change-53.56%-5.84%
EPS (TTM)$-0.57$-0.36
Dividend yield0.00%0.00%
Annual dividend$0.00$0.00
Revenue (latest FY)—$451.00K
Net income (latest FY)$-12.60M$-1.03M
Gross margin—0.67%
Operating margin—-481.60%
Net margin—-227.72%
52-week high$1.49$5.64
52-week low$0.2036$1.37
Distance from 52-week high-84.63%-75.71%
Analyst consensusnone—
Avg. price target upside+1528.82%—
Average volume388.67K6.58K
Shares outstanding14.19M2.46M
Employees84
SectorHealth CareHealth Care
IndustryBiotechnology: Pharmaceutical PreparationsBiotechnology: Pharmaceutical Preparations

Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.

About Aprea Therapeutics

APRE stock →

Aprea Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing novel synthetic lethality-based cancer therapeutics that targets DNA damage response pathways. Its lead product candidates are APR-1051, an orally bioavailable small-molecule inhibitor of WEE1 kinase that is in Phase 1 clinical trial for the treatment of patients with advanced solid tumors with biomarkers and ATRN-119, an ATR inhibitor, which is in Phase 1/2a clinical trial for solid tumor indications.

Health Care · Biotechnology: Pharmaceutical Preparations · 8 employees

About XTL Biopharmaceuticals

XTLB stock →

XTL Biopharmaceuticals Ltd., a biopharmaceutical company, engages in the acquisition and development of pharmaceutical drugs for the treatment of autoimmune diseases in Israel. The company's lead drug candidate is hCDR1, which is a Phase II-ready asset for the treatment of systemic lupus erythematosus and Sjogren's syndrome.

Health Care · Biotechnology: Pharmaceutical Preparations · 4 employees

APRE vs XTLB FAQ

Which is bigger, Aprea Therapeutics or XTL Biopharmaceuticals?

XTL Biopharmaceuticals (XTLB) is larger, with a market capitalization of $3.37M compared with $3.25M for Aprea Therapeutics (APRE).

Are Aprea Therapeutics and XTL Biopharmaceuticals in the same industry?

Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.

More comparisons